Ignite Creation Date:
2024-05-06 @ 3:10 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04542044
Status:
COMPLETED
Last Update Posted:
2020-09-09
First Post:
2020-09-02
Brief Title:
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia
Sponsor:
University Hospital Geneva
Organization:
University Hospital Geneva
Study Overview
Official Title:
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia PneumoCoV-Ambu
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PneumoCoV-Ambu
Brief Summary:
The purpose of this study is to evaluate the strategy of investigators for outpatients SARS-CoV-2 moderate pneumonia management in terms of efficacy and patient safety The investigators ultimate goal is to validate first wave management strategy in order to support the investigators future approach in the event of a second wave and spare the hospital resources by safely keeping at home as many patients as possible
Detailed Description:
The investigators focused on participants consulting in the emergency department at the HUG who remained in an outpatient setting with pneumonia and moderate illness defined by individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen SaO2 93 on room air and no other hospitalization criteria CURB 65 score below 2points
For patients follow-up the investigators have created an aftercare ambulatory unit open 57 days The investigators were able to conduct 64 consultations between April 2 and May 5 2020 Every participant had suspected or confirmed SARS-CoV-2 pulmonary tract infection
The follow-up data was entered into DPI patients medical record at HUG on a specific consultation form Patients followed in the investigators consultation were contacted between 30 and 60 days after diagnosis by the Covicare team The Covicare team is call-center composed of medical students and primary care physicians who remotely followed patients with COVID-19 by calling them by phone or telemedicine every day or every other day depending on patients needs and health status The investigators will export data from RedCap concerning post-hospitalization satisfaction survey on our care and oral consent for use of data ARGOS study CCER number 2020-01273
For patients follow-up the investigators have created an aftercare ambulatory unit open 57 days The investigators were able to conduct 64 consultations between April 2 and May 5 2020 Every participant had suspected or confirmed SARS-CoV-2 pulmonary tract infection
The follow-up data was entered into DPI patients medical record at HUG on a specific consultation form Patients followed in the investigators consultation were contacted between 30 and 60 days after diagnosis by the Covicare team The Covicare team is call-center composed of medical students and primary care physicians who remotely followed patients with COVID-19 by calling them by phone or telemedicine every day or every other day depending on patients needs and health status The investigators will export data from RedCap concerning post-hospitalization satisfaction survey on our care and oral consent for use of data ARGOS study CCER number 2020-01273
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None